Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA.
Cancer. 2012 Jan 1;118(1):188-95. doi: 10.1002/cncr.26237. Epub 2011 Jun 29.
Disclosure of conflicts of interest in biomedical research is receiving increased attention. The authors sought to define current disclosure policies and how they relate to disclosure statements provided by authors in major oncology journals.
The authors identified all oncology journals listed in the Thomson Institute for Scientific Information and sought their policies on conflict-of-interest disclosure. For a subset of journals with an Impact Factor >2.0, they catalogued the number and type of articles and the details of the published disclosures in all papers from the 2 most recent issues.
Disclosure policies were provided by 112 of 131 journals (85%); 99 (88%) of these requested that authors disclose conflicts of interest (mean Impact Factor for these journals: 4.6), whereas the remaining 13 (12%) did not (mean Impact Factor: 2.9). Ninety-three journals (94%) required financial disclosure, and 42 (42%) also sought nonfinancial disclosures. For a subset of 52 higher-impact journals (Impact Factor >2.0), we reviewed 1734 articles and identified published disclosures in 51 journals (98%). Many of these journals (31 of 51, 61%) included some disclosure statement in >90% of their articles. Among 27 journals that published editorials/commentaries, only 14 (52%) included disclosures with such articles. There was no publication of any nonfinancial conflicts of interest in any article reviewed.
Disclosure policies and the very definition of conflict of interest varied considerably among journals. Although most journals had some policy in this area, a substantial proportion did not publish disclosure statements consistently, with deficiencies particularly among editorials and commentaries.
生物医学研究中的利益冲突披露受到越来越多的关注。作者旨在定义当前的披露政策,以及它们与主要肿瘤学期刊作者提供的披露声明之间的关系。
作者确定了汤森路透科学信息研究所列出的所有肿瘤学期刊,并寻求其利益冲突披露政策。对于影响因子>2.0 的期刊子集,他们对最近两期所有论文的文章数量和类型以及已发表披露的详细信息进行了编目。
131 种期刊中有 112 种(85%)提供了披露政策;其中 99 种(88%)要求作者披露利益冲突(这些期刊的平均影响因子为 4.6),而其余 13 种(12%)期刊不要求披露(平均影响因子为 2.9)。93 种期刊(94%)要求财务披露,42 种期刊(42%)还寻求非财务披露。对于影响因子>2.0 的 52 种高影响力期刊的子集,我们审查了 1734 篇文章,并在 51 种期刊(98%)中确定了已发表的披露。这些期刊中有许多(31 种,61%)在其超过 90%的文章中包含了一些披露声明。在发表社论/评论的 27 种期刊中,只有 14 种(52%)在这些文章中包含了披露。在我们审查的任何文章中都没有发布任何非财务利益冲突的信息。
期刊之间的披露政策和利益冲突的定义差异很大。尽管大多数期刊在这方面都有一些政策,但相当一部分期刊没有一致地发布披露声明,尤其是在社论和评论中存在缺陷。